

[Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio](#)

24th November, 2009

Aflac Incorporated

COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by ORLANDO, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Two thirds of adults are overweight and one third of those are obese. Experts estimate that 80 percent of the population will experience a back

[WellTek Positioned to Capitalize on Trends in Health and Fitness](#)

24th November, 2009

WellTek Incorporated

Boron Biologicals Incorporated Patents:



- 5659027- [Boronated compounds](#)
- 5143907- [Phosphite-borane compounds, and method of making and using the same](#)
- 5177198- [Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates](#)
- 5254706- [Process of making phosphite-borane compounds](#)
- 5256394- [Radiological imaging method, and contrast media reagents therefor](#)
- 5280119- [Heterocyclic amine-boranes, and method of inhibiting DNA topoisomerase activity and/or combatting inflammation, hyperlipidemia, and/or neoplasia using amine-borane compounds](#)
- 5286853- [Boron-gadolinium compounds and method of conducting imaging and/or neutron capture therapy with same](#)
- 5312816- [Method of combatting osteoporosis in mammalian subjects, utilizing organic boron compounds](#)
- 5362732- [Boronated compounds](#)
- 5399732- [Phosphite-borane compounds, and method of making and using the same](#)
- 5434143- [Pharmaceutical compositions comprising phosphite-borane compounds](#)
- 5455233- [Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates](#)
- 5545397- [Contrast agents and compositions for radiological imaging, and radiological imaging method utilizing same](#)
- 5595878- [Detection of biopolymers and biooligomers with boron hydride labels](#)
- 5023513- [Amine-alkylborane derivatives and methods](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

